CancerTYPE ID®

Resolve ambiguous diagnoses, reveal therapeutic targets, and identify clinical trial options with one sample submission.

NeoGenomics and Biotheranostics, Inc., a Hologic Company, are pleased to provide a combined test offering for metastatic cancer patients with an unknown or unclear diagnosis.  CancerTYPE ID^® with reflex to NeoTYPE^® Cancer Profile enables tumor type classification and identification of actionable biomarkers in a seamless, single-order process that is available from either company.

CancerTYPE ID^® Performance

CancerTYPE ID^® is a proprietary molecular assay using RT-PCR to measure expression of 92 genes. To classify the tumor, the gene expression profile is matched to a database of more than 2000 known tumor types and subtypes. Using this technology, CancerTYPE ID^® can identify 50 different tumor types and subtypes, covering >95% of all solid tumors based on incidence.¹ The test reports a main cancer type with the highest probability, as well as a list of tumor types that may be ruled out with 95% confidence.

Extensively validated, CancerTYPE ID^® has demonstrated 87% accuracy in a multi-institutional validation study led by three Centers of Excellence: UCLA, Mayo Clinic, and MGH.² A comparison vs. standard of care IHC also showed that when more than 7-9 stains were required for analysis, the accuracy of IHC fell below 50%, while CancerTYPE ID^® maintained significantly higher performance, and therefore may provide a tissue-sparing approach to establish the tumor type in these challenging cases.³ In a prospective clinical trial led by the Sarah Cannon Research Institute, CancerTYPE ID^® identified a primary tumor type in 98% of cases and therapy based on the CancerTYPE ID^® result improved overall survival by 37%.⁴

Clinical Significance

Determining a single tumor type diagnosis is essential for an oncologist’s ability to effectively treat his or her patient. Although recent studies have investigated whether molecular alterations alone are sufficient to direct treatment, results have had limited actionability due to inconsistent efficacy of the treatments across multiple tumor types.⁵ Thus, a definitive diagnosis of the tumor type remains a critical first step for appropriate treatment.

While IHC is the standard of care method used to establish an initial pathologic diagnosis, metastatic disease often poses diagnostic challenges, resulting in over 100,000 cases per year that still have some degree of diagnostic ambiguity.^6-8 For these difficult-to-diagnose metastatic cases, CancerTYPE ID^® provides important tumor type information to resolve diagnostic dilemmas. It can help narrow a differential diagnosis so that clients may confidently report a single final diagnosis⁹ and efficiently identify targetable mutations in genes pre-selected for their known impact in that tumor type.